Fresh analysis suggests that patients who discontinue popular slimming jabs like semaglutide or tirzepatide may regain reduced body mass much more quickly than those who stop traditional lifestyle programs.
Research printed in a leading medical journal shows that while obese people can lose a large proportion of their total mass while using the jabs, the mass returns at an average rate of 0.8 kg per month upon discontinuation.
"Users purchasing these medications must be informed of the potential of rapid weight regain when the treatment is stopped," cautioned lead investigator Dr. Susan Jebb.
Such speed of recovery suggests a reversion to original mass within about a year and a half.
Comparing Treatments
The study, which reviewed dozens of trials involving thousands of participants, contrasted the outcomes of these new drugs with conventional dieting.
Scientists note that people who lose weight through lifestyle changes alone generally have a more gradual creep back—perhaps 100 grams monthly—once they finish.
The Reason for the Quick Regain
Nutrition scientists suggest the way of the injections is key to understanding the amplified weight return.
GLP-1 drugs imitate a natural hormone called GLP-1, which moderates hunger.
"Long-term administration of GLP-1 concentrations several times higher than normal could lead to the body to generate a reduced amount of its own natural hormone, and may also diminish responsiveness to its actions," said Dr. Adam Collins, a dietetics researcher.
"Stopping of this GLP-1 'fix' leads to hunger is no longer kept in check, making overeating much more probable."
A Lifelong Disease?
Medical guidelines recommend the injections for individuals with weight-linked medical conditions, alongside prescribed diet and exercise modifications.
A number of clinicians say that, due to the significant potential of weight regain, the therapy should be considered life-long.
This perspective is echoed by pharmaceutical companies, who note that the findings "emphasize the chronic nature of obesity," akin to managing conditions like diabetes.
User Experiences
People who have come off the jabs report a intense return of hunger.
"It was like a switch activating and you're instantly ravenous," said a patient.
This difficulty is compounded if individuals have not established lasting dietary or behavioural modifications during therapy.
Widespread Adoption
Figures suggest that millions of people in the UK have tried these injections in the last 12 months, with interest remaining high.
- Use is higher among women compared to men.
- The 40s and 50s demographic shows the highest level of interest.
- Many access the medications through private healthcare rather than public health services.
Ultimately, clinicians stress that while these medications are potent tools for weight loss, they are not a standalone fix and maintained weight loss relies on ongoing behavioural support.
